Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.56M | 7.02M | 9.98M | 8.30M | 6.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.56M | 7.02M | 9.98M | 8.30M | 6.07M |
| Cost of Revenue | 184.50M | 163.55M | 147.04M | 136.31M | 122.87M |
| Gross Profit | -176.94M | -156.53M | -137.06M | -128.01M | -116.80M |
| SG&A Expenses | 40.27M | 38.55M | 37.12M | 35.28M | 33.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 224.77M | 202.10M | 184.15M | 171.59M | 156.25M |
| Operating Income | -217.21M | -195.08M | -174.18M | -163.29M | -150.18M |
| Income Before Tax | -178.85M | -157.86M | -154.08M | -150.22M | -144.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -178.85 | -157.86 | -154.08 | -150.22 | -144.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.85M | -157.86M | -154.08M | -150.22M | -144.88M |
| EBIT | -217.21M | -195.08M | -174.18M | -163.29M | -150.18M |
| EBITDA | -213.94M | -191.90M | -171.06M | -160.19M | -147.12M |
| EPS Basic | -2.70 | -2.45 | -2.57 | -2.74 | -2.84 |
| Normalized Basic EPS | -1.69 | -1.53 | -1.45 | -1.56 | -1.63 |
| EPS Diluted | -2.70 | -2.45 | -2.57 | -2.74 | -2.85 |
| Normalized Diluted EPS | -1.69 | -1.53 | -1.45 | -1.56 | -1.63 |
| Average Basic Shares Outstanding | 265.05M | 257.54M | 243.21M | 224.18M | 205.41M |
| Average Diluted Shares Outstanding | 265.05M | 257.54M | 243.21M | 224.18M | 205.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |